Anti-PD-L1 nano antibody

By designing specific anti-human PD-L1 nano-antibody and fusion protein, the problems of traditional antibody drugs with large molecular weight, poor penetration and high immunogenicity in tumor treatment are solved, and high affinity, low immunogenicity and stability are achieved , significantly improves tumor suppression effect.

CN119019558APending Publication Date: 2024-11-26ZHEJIANG DOER BIOLOGICS CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411026014.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2019-08-22
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing antibody drugs have problems such as large molecular weight, poor penetration, high immunogenicity, high production cost and poor stability when treating tumors. Especially, nano-antibodies face high affinity and specificity challenges in application, resulting in Its application in clinical practice is limited.

Method used

An anti-human PD-L1 nanoantibodies were developed that contain specific complementary determining region CDRs and framework region amino acid sequences, combining high affinity and low immunogenicity, and prolonged in vivo by design of fusion proteins and immunoconjugates. Half-life and enhancement of cooperative effects on effector cells.

Benefits of technology

Antibody preparation with high affinity, low immunogenicity and stability is achieved, which significantly improves the blocking effect and tumor suppression ability of PD-L1/PD-1 interaction, enhances the therapeutic effect, and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004968546790000201
    Figure BDA0004968546790000201
  • Figure BDA0004968546790000202
    Figure BDA0004968546790000202
  • Figure BDA0004968546790000203
    Figure BDA0004968546790000203
Patent Text Reader

Abstract

The invention provides a nano antibody for specifically resisting PD-L1 and blocking PD-L1 / PD-1 interaction, a humanized antibody prepared on the basis of the nano antibody, a fusion protein and application of the humanized antibody and the fusion protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the biological field, and in particular to anti-human PD-L1 nanoantibodies and applications thereof. Background Art

[0002] Programmed death 1 ligand 1 (PD-L1) was originally cloned as a member of the B7 protein family (called B7-H1) (Dong et al., 1999 Nature Med 5:1365). PD-L1 belongs to type I transmembrane protein, with a total of 290 amino acids, including 1 IgV-like region, 1 IgC-like region, 1 transmembrane hydrophobic region and 1 intracellular region composed of 30 amino acids. PD-L1 is widely expressed on the surface of various immune cells, epithelial cells and tumor cells. PD-L1 binds to the programmed death-1 (PD-1) receptor and activates the negative regulatory signal transduction pathway, thereby inhibiting T cell activation or inducing T cell apoptosis, so that the immune response is suppressed (Freeman et al., 2000 J Exp Med 192:1027). During tumor development, cancer cells will induce T cell apoptosis by upregulating PD-L1 expression to avoid its clearance by the immune system, thereby leading to disease progression. In recent years, monoclonal antibody drugs targeting PD-1 / PD-L1 proteins have been used to block the binding of PD-1 / PD-L1, thereby promoting the activation and proliferation of T cells in the body to kill tumor cells. They have been used in the treatment of various tumors, such as melanoma, lymphoma, bladder cancer, non-small cell lung cancer, head and neck cancer, colon cancer, etc., and have achieved significant therapeutic effects. Therefore, the PD1 / PD-L1 pathway has become an important target for anti-tumor drug research. At present, antibody drugs that inhibit the PD1 / PD-L1 pathway have achieved great success in clinical practice. Among them, Nivolumab from Bristol-Myers Squibb, MK-3475 from Merck and MPDL3280A from Roche have been launched one after another. Antibody drugs targeting the PD1 / PD-L1 pathway will become the most promising field in the tumor treatment market.

[0003] The successful application of monoclonal antibodies in cancer detection and biological targeted therapy has led to a revolution in tumor treatment. However, the molecular weight of traditional monoclonal antibodies (about 150kD) is too large and difficult to penetrate tissues, resulting in low effective concentrations in tumor areas and insufficient therapeutic effects; traditional antibodies have high immunogenicity, while modified antibodies are difficult to achieve the original affinity. In addition, many factors such as the long development cycle, high production cost, and insufficient stability of fully humanized traditional antibodies limit their application and popularization in clinical practice. The subsequent emergence of nanoantibodies has the smallest functional antigen-binding fragment derived from the heavy chain antibody in adult camels, which has high stability and high affinity for binding to antigens. Nanoantibodies have many unique properties compared to conventional antibodies: 1) The sequence encoded by nanoantibodies has high homology with human VH families 3 and 4, making it weakly immunogenic; 2) Nanoantibodies have a small molecular weight of only about 15kDa, a simple structure, and are easy to express in large quantities in microorganisms and easy to purify. The unique properties and low cost of nanoantibodies have greatly expanded their application range, showing their value in the treatment and diagnosis of diseases. However, in the prior art, it is still difficult for those skilled in the art to screen nano antibodies, and it is not easy to obtain nano antibodies with high affinity, high specificity and industrial prospects. The screening of antibodies that only use three complementary determining regions (CDRs) to bind to antigens is much more difficult than that of antibodies that use six CDR regions to bind to antigens. This also makes the mainstream antibodies that are currently truly commercialized or under preclinical research still monoclonal antibodies with larger molecular weight. Not only that, the nano antibodies currently obtained in this field also have many problems in application, such as immunogenicity (ADA) problems caused by their special structure. TAS266 is an anti-DR5 receptor nano antibody, and its development was suspended in Phase I clinical research due to severe liver toxicity. Further studies have found that its liver toxicity is closely related to the ADA present in the subject (Papadopoulos, KP, Isaacs, R., Bilic, S. et al. Cancer Chemother Pharmacol (2015) 75: 887.). In another phase I clinical trial of an anti-TNFR1 VHH antibody (GSK1995057), the clinical study was also terminated due to the presence of ADA in the subjects, which led to a cytokine storm (Journal of Clinical Immunology, 2013, Volume 33, Number 7, Page 1192 M.C. Holland, JU Wurthner, PJ Morley). In order to maintain high affinity and stability without light chains, the framework region and CDR of single heavy chain antibodies (VHH) are somewhat different from those of conventional human antibodies. In particular, the structure of CDR3 is often more different.In many cases, the amino acid composition and length of the CDR3 region of the high-affinity VHH obtained by screening are quite different from those of human antibody sequences (Nature (1993) 363: 446-8; Protein Eng (1994) 7: 1129-35.; Mol Immunol (1997) 34: 1121-31). For example, the CDR3 region of high-affinity VHH is often longer, often contains Cys, and even forms disulfide bonds (Protein Engineering, Design & Selection, 24 (9): 727tein, 2011). In the PDL1-56 sequence of SEQ ID NO:28 in WO2017 / 020801A1, CDR1 and CDR3 (encoded according to IMGT) each have one Cys. The two added cysteines will significantly increase the probability of disulfide bond mismatch, resulting in misfolding; and the pair of disulfide bonds formed by the two added cysteines will increase the difference between it and human antibodies, and the risk of immunogenicity may increase. As we all know, the greater the difference from the human sequence, the lower the degree of humanization, the higher the potential immunogenicity, and the higher the possibility of the human body producing anti-VHH antibodies when used in the human body. The immunogenicity of biological drugs often determines the effectiveness and safety of their clinical application, and is a key to their successful development for clinical use. An important contribution of the present invention is the screening of some VHH sequences that have high affinity but are very close to the structure of human antibodies. Summary of the invention

[0004] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide an anti-human PD-L1 nanobody to solve the problems in the prior art.

[0005] To achieve the above-mentioned and other related purposes, in a first aspect of the present invention, an anti-PD-L1 nanobody is provided, wherein the complementary determining region CDR comprises CDR1 to CDR3 with the amino acid sequences shown below: (1) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 15, and CDR3 shown in SEQ ID NO: 25; or (2) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 16, and CDR3 shown in SEQ ID NO: 26; or (3) CDR1 shown in SEQ ID NO: 8, CDR2 shown in SEQ ID NO: 16, and CDR3 shown in SEQ ID NO: 27; or (4) CDR1 shown in SEQ ID NO: 9, CDR2 shown in SEQ ID NO: 17, and CDR3 shown in SEQ ID NO: 28; or (5) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 16, and CDR3 shown in SEQ ID NO: 29; or (6) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12. CDR2 shown in NO:18, CDR3 shown in SEQ ID NO:30.

[0006] In a preferred example, the anti-PD-L1 nanobody further includes a framework region FR, wherein the framework region FR includes FR1 to FR4 with the amino acid sequences shown below: (1') FR1 shown in SEQ ID NO: 1, FR2 shown in SEQ ID NO: 11, FR3 shown in SEQ ID NO: 19, and FR4 shown in SEQ ID NO: 31; or (2') FR1 shown in SEQ ID NO: 2, FR2 shown in SEQ ID NO: 12, FR3 shown in SEQ ID NO: 20, and FR4 shown in SEQ ID NO: 31; or (3') FR1 shown in SEQ ID NO: 3, FR2 shown in SEQ ID NO: 13, FR3 shown in SEQ ID NO: 21, and FR4 shown in SEQ ID NO: 31; or (4') FR1 shown in SEQ ID NO: 4, FR2 shown in SEQ ID NO: 13, FR3 shown in SEQ ID NO: 22, and FR4 shown in SEQ ID NO: 31; or (5') FR1 shown in SEQ ID NO: 5, FR2 shown in SEQ ID NO: 12, FR3 shown in SEQ ID NO: 23, and FR4 shown in SEQ ID NO: 31. or (6′) FR1 shown in SEQ ID NO:5, FR2 shown in SEQ ID NO:14, FR3 shown in SEQ ID NO:24, or FR4 shown in SEQ ID NO:31.

[0007] In another preferred example, the anti-PD-L1 nanobody includes: (a) a nanobody having an amino acid sequence as shown in any one of SEQ ID NOs: 33 to 38; or (b) a nanobody having an amino acid sequence that is more than 80% (such as 85%, 90%, 93%, 95%, 97% or 99% or more) identical to the sequence shown in any one of SEQ ID NOs: 33 to 38 and having the function of (a) nanobody.

[0008] In another preferred example, the anti-PD-L1 nanobody is a humanized antibody, and preferably, its framework region FR includes FR1 to FR4 of an amino acid sequence selected from the following group: FR1 shown in SEQ ID NO: 3; FR2 shown in SEQ ID NOs: 59 to 61; FR3 shown in SEQ ID NOs: 62 to 64; FR4 shown in SEQ ID NO: 65.

[0009] In another preferred embodiment, the FR1 shown in SEQ ID NO: 3 is used as the FR1 of any one of the Nanobodies described in (1) to (6).

[0010] In another preferred example, FR2 shown in SEQ ID NO:59 is used as FR2 of the nanobody (1); FR2 shown in SEQ ID NO:60 is used as FR2 of the nanobody (2) or (5); FR2 shown in SEQ ID NO:61 is used as FR2 of the nanobody (3), (4) or (6).

[0011] In another preferred example, the FR3 shown in SEQ ID NO:62 is used as the FR3 of the nanobody (1); the FR3 shown in SEQ ID NO:63 is used as the FR3 of the nanobody (2), (3), (5) or (6); and the FR3 shown in SEQ ID NO:64 is used as the FR3 of the nanobody (4).

[0012] In another preferred embodiment, the FR4 shown in SEQ ID NO: 65 is used as the FR4 of any one of the Nanobodies described in (1) to (6).

[0013] In another preferred example, the anti-PD-L1 nanobody is a humanized antibody, including: (i) a nanobody with an amino acid sequence as shown in any one of SEQ ID NOs: 39 to 44; or (ii) a nanobody with an amino acid sequence that is more than 80% (such as 85%, 90%, 93%, 95%, 97% or 99% or more) identical to the sequence shown in any one of SEQ ID NOs: 39 to 44 and having the function of (i) nanobody.

[0014] In another aspect of the present invention, a fusion protein is provided, comprising: a first domain, which is the aforementioned nanobody; and a second domain, which has the effect of prolonging the half-life in vivo and / or has a binding effect on effector cells.

[0015] In a preferred example, the second domain includes (but is not limited to): an immunoglobulin Fc region, preferably a human immunoglobulin Fc region; and / or serum albumin (such as human HSA) or a fragment thereof, a domain that binds serum albumin (such as an anti-serum albumin antibody, including nanobodies), polyethylene glycol, a polyethylene glycol-liposome complex, or a combination thereof; and / or a molecule that has affinity for T cell surface molecules and / or is capable of binding to surface molecules present on T cells; preferably, the surface molecules include (but are not limited to): CD3.

[0016] In another preferred embodiment, the human immunoglobulin Fc region includes mutations for changing Fc-mediated effector functions, and the effector functions include a combination of one or more of CDC activity, ADCC activity, and ADCP activity.

[0017] In another preferred embodiment, the immunoglobulin is a combination of one or more selected from IgG, IgA1, IgA2, IgD, IgE, and IgM, and the IgG is a combination of one or more selected from IgG1, IgG2, IgG3, or IgG4 subtypes.

[0018] In another preferred embodiment, the amino acid sequence of the immunoglobulin Fc region is selected from one of SEQ ID NOs: 45 to 48.

[0019] In another preferred embodiment, a connecting peptide is provided between the first domain and the second domain; the connecting peptide is preferably selected from a flexible polypeptide chain composed of alanine and / or serine and / or glycine, and the length of the connecting peptide is preferably 3 to 30 amino acids.

[0020] In another aspect of the present invention, an isolated polynucleotide is provided, encoding any of the aforementioned nanoantibodies, or encoding any of the aforementioned fusion proteins.

[0021] In another aspect of the present invention, a construct is provided, comprising the isolated polynucleotide.

[0022] In another aspect of the present invention, an antibody expression system is provided, wherein the expression system contains the construct or the exogenous polynucleotide is integrated into the genome; preferably, the expression system is a cell expression system.

[0023] In another preferred embodiment, the antibody expression system is used for expression under conditions suitable for expressing the antibody, thereby expressing the antibody or fusion protein; preferably, the antibody or fusion protein is purified and isolated.

[0024] In another aspect of the present invention, an immunoconjugate is provided, comprising: (A) any of the aforementioned Nanobodies, or any of the aforementioned fusion proteins; and (B) a functional molecule connected to (A) (including but not limited to covalently linked, coupled, attached, adsorbed).

[0025] In another preferred embodiment, (B) includes (but is not limited to): cytotoxins, radioactive isotopes, biologically active proteins, molecules targeting tumor surface markers, molecules that inhibit tumors, molecules or detectable markers targeting surface markers of immune cells, extracellular hinge regions, transmembrane regions and intracellular signaling regions based on chimeric antigen receptor technology (CAR), or a combination thereof.

[0026] In another preferred embodiment, the molecule targeting the tumor surface marker is an antibody or a ligand that binds to the tumor surface marker; or the molecule inhibiting the tumor is an anti-tumor cytokine or an anti-tumor toxin.

[0027] In another preferred embodiment, the cytokines include (but are not limited to): IL-12, IL-15, IFN-beta, TNF-alpha.

[0028] In another preferred embodiment, the detectable markers include (but are not limited to): fluorescent markers and colorimetric markers.

[0029] In another preferred embodiment, the antibody that binds to a tumor surface marker is an antibody that recognizes antigens other than PD-L1, and the other antigens include (but are not limited to): EGFR, EGFRvIII, mesothelin, HER2, EphA2, Her3, EpCAM, MUC1, MUC16, CEA, Claudin 18.2, folate receptor, Claudin 6, WT1, NY-ESO-1, MAGE3, ASGPR1 or CDH16.

[0030] In another preferred embodiment, the intracellular signal region is such as but not limited to: CD3ζ chain, FcεRIγ tyrosine activation motif, intracellular signal region of co-stimulatory signal molecules CD27, CD28, CD137, CD134, MyD88, CD40, etc.; or the transmembrane region is such as but not limited to: the transmembrane region of CD8 or CD28.

[0031] In another aspect of the present invention, a pharmaceutical composition (including a diagnostic composition, such as a diagnostic reagent) is provided, which comprises any of the aforementioned nanoantibodies, or any of the aforementioned fusion proteins, or any of the aforementioned immunoconjugates.

[0032] In another preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0033] In another aspect of the present invention, there is provided the use of the Nanobody, the fusion protein, the immunoconjugate, or the pharmaceutical composition in the preparation of a preparation, a kit or a medicine kit for diagnosing, treating or preventing cancer.

[0034] In another preferred embodiment, the cancer includes: lung cancer, melanoma, gastric cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, classical Hodgkin's lymphoma, hematological malignancies, head and neck cancer or nasopharyngeal carcinoma, or a combination thereof.

[0035] In another aspect of the present invention, there is provided a use of the nanobody, or the fusion protein, or the immunoconjugate, or the pharmaceutical composition in the preparation of a drug for treating or preventing an infectious disease or a chronic inflammatory disease.

[0036] In another aspect of the present invention, a kit or a medicine kit is provided, comprising the nanobody, or the fusion protein, or the immunoconjugate, or the pharmaceutical composition.

[0037] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 , the blocking curve of the Anti-PDL1-Fc fusion protein of the present invention on the PD-L1 / PD-1 interaction.

[0039] Figure 2 , and a luciferase detection kit was used to detect the effect of the Anti-PDL1-Fc fusion protein of the present invention on the immune response of Jurkat cells.

[0040] Figure 3 , the effect of the Anti-PDL1-Fc fusion protein of the present invention on the IL-2 secretion of mixed lymphocytes.

[0041] Figure 4 , the inhibitory effect of the Anti-PDL1-Fc fusion protein of the present invention on tumor growth. DETAILED DESCRIPTION

[0042] After extensive screening and in-depth research, the inventors have revealed a class of nanobodies that are specific against PD-L1 and block the PD-L1 / PD-1 interaction; also disclosed humanized antibodies and fusion proteins prepared based on the nanobodies; and also disclosed their applications.

[0043] the term

[0044] As used herein, the terms "programmed death-ligand 1", "PD-ligand 1", "PD-L1", "PDL1", "B7 homolog 1", "B7-H1", "CD274" are used interchangeably and include variants, isoforms, species homologs of human PD-L1, and analogs having at least one common epitope of PD-L1.

[0045] The term "antibody" or "immunoglobulin" is used as a general term to include full-length antibodies, their individual chains, and all parts, domains or fragments thereof (including but not limited to antigen binding domains or fragments, such as VHH domains or VH / VL domains, respectively) whether referring to heavy chain antibodies or conventional 4-chain antibodies herein. In addition, the term "sequence" used herein (e.g., in terms of "immunoglobulin sequence", "antibody sequence", "single variable domain sequence", "VHH sequence" or "protein sequence", etc.) is generally understood to include both the relevant amino acid sequence and the nucleic acid sequence or nucleotide sequence encoding the sequence, unless a more limited explanation is required herein.

[0046] The term "monoclonal antibody" refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope.

[0047] The term "domain" (of a polypeptide or protein) refers to a folded protein structure that is able to maintain its tertiary structure independently of the rest of the protein. In general, a domain is responsible for a single functional property of a protein and in many cases can be added, removed or transferred to other proteins without loss of the function of the rest of the protein and / or the domain.

[0048] The terms "single (structural) domain antibody (VHH)" and "nanobody" have the same meaning, referring to cloning the variable region of the antibody heavy chain to construct a single domain antibody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with complete functions. Usually, antibodies that naturally lack the light chain and heavy chain constant region 1 (CH1) are first obtained from alpaca immune serum, and then the variable region of the antibody heavy chain is cloned to construct a single domain antibody (VHH) consisting of only one heavy chain variable region.

[0049] The term "single (structural) domain antibody (VHH)" refers to an immunoglobulin domain comprising four "framework regions" referred to in the art and hereinafter as "framework region 1" or "FR1", "framework region 2" or "FR2", "framework region 3" or "FR3", and "framework region 4" or "FR4", respectively, wherein the framework regions are separated by three "complementarity determining regions" or "CDRs" referred to in the art and hereinafter as "complementarity determining region 1" or "CDR1", "complementarity determining region 2" or "CDR2", and "complementarity determining region 3" or "CDR3". Therefore, the general structure or sequence of a single domain antibody (VHH) can be represented as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. A single domain antibody (VHH) confers specificity to an antigen by having an antigen binding site.

[0050] The terms “heavy chain single domain antibody”, “VHH domain”, “VHH”, “VHH antibody fragment”, “VHH antibody” and “Nanobody” (“Nanobody” is a trademark of Ablynx NV, Ghent, Belgium) are used interchangeably.

[0051] The term "IMGT numbering system" is an integrated information system specifically for immunoglobulins (IG), T cell receptors (TCR) and major histocompatibility complex (MHC) in humans and other vertebrates, namely THE INTERNATIONAL IMMUNOGENETICS INFORMATION (Lafranc et al., 2003, Dev. Comp. Immunol. 27 (1): 55-77). Log in to IMGT (http: / / www.imgt.org / IMGT_vquest) and analyze the antibody light and heavy chain genes to determine the framework regions (FR) and complementarity determining regions (CDR) of the variable region. The "position" of CDR within the structure of the immunoglobulin variable domain is conserved between species and exists in a structure called a loop, so it is easy to identify CDR and framework residues by using a numbering system that aligns the variable domain sequence according to structural features. This information can be used to transplant and replace CDR residues from an immunoglobulin of one species into an acceptor framework that is usually from a human antibody. Unless otherwise indicated, in this specification, claims and drawings, anti-PD-L1 nanobodies are numbered according to the IMGT numbering system method to determine CDR regions and FR regions.

[0052] The term "humanized antibody" refers to a molecule having an antigen binding site substantially derived from an immunoglobulin of a non-human species, wherein the remaining immunoglobulin structure of the molecule is based on the structure and / or sequence of a human immunoglobulin. The antigen binding site may comprise a complete variable domain fused to a constant domain, or may comprise only a complementarity determining region (CDR) transplanted into an appropriate framework region in a variable domain. The antigen binding site may be wild type, or modified by one or more amino acid substitutions, such as modification to be closer to a human immunoglobulin. Certain forms of humanized antibodies retain all CDR sequences (e.g., humanized nanobodies containing all three CDRs from alpacas). Other forms have one or more CDRs that have been altered relative to the original antibody.

[0053] The term "aggregates": The protein structure is stabilized by non-covalent interactions and disulfide bonds between two cysteine ​​residues. Non-covalent interactions include ionic interactions and weak van der Waals interactions. Ionic interactions are formed between anions and cations and form salt bridges, which help stabilize proteins. They play an important role in the secondary structure of proteins, such as the formation of alpha helices or beta folds, as well as tertiary structures. The interactions between amino acid residues in a particular protein are very important in the final structure of the protein. In vitro or extracellular, common in the industrial preparation of active proteins, when the environment in which the active protein is located, such as pH, concentration, ionic strength or temperature changes, the non-covalent interactions between amino acids change, resulting in the exposed hydrophobic part of one protein molecule may interact with the exposed hydrophobic region of other protein molecules, thereby forming amorphous aggregates, oligomers and high molecular weight aggregates. Aggregates affect the stability of active proteins. In vivo, the formation of aggregates easily triggers the clearance response of the immune system, accelerates drug clearance and may bring immune risks to the body.

[0054] "Sequence identity" between two polypeptide sequences indicates the percentage of identical amino acids between the sequences. "Sequence similarity" indicates the percentage of amino acids that are identical or represent conservative amino acid substitutions. Methods for evaluating the degree of sequence identity between amino acids or nucleotides are known to those skilled in the art. For example, amino acid sequence identity is typically measured using sequence analysis software. For example, the BLAST program of the NCBI database can be used to determine identity.

[0055] An "effective amount" of an agent is that amount necessary to effect a physiological change in the cell or tissue to which it is administered.

[0056] A "therapeutically effective amount" of an agent, such as a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or preventive result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes or prevents the adverse effects of a disease.

[0057] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Preferably, the individual or subject is a human.

[0058] The term "pharmaceutical composition" refers to a preparation which is in such form that the biological activity of the active ingredient contained therein is effective, and which contains no additional ingredients which would be unacceptably toxic to a subject to which the composition would be administered.

[0059] "Pharmaceutically acceptable carrier" refers to a component other than the active ingredient in a pharmaceutical composition that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.

[0060] The term "treatment / prevention" (and grammatical variations thereof) refers to an attempt to alter the natural course of a disease in a treated individual, and may be a clinical intervention performed for prevention or during the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, ameliorating or alleviating the disease state, and eliminating or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the development of a disease or slow the progression of a condition.

[0061] The term "detectable marker" refers to a marker that can be attached to an antibody and used to determine the presence or absence and amount of a specific target in a subject to be detected. The "detectable marker" can be, but is not limited to: an enzyme, a fluorescent marker, a nuclide, a quantum dot, colloidal gold, etc. More specifically, for example, it can be selected from: horseradish peroxidase (HRP), alkaline phosphatase (AP), glucose oxidase, β-D-galactosidase, urease, catalase, or glucoamylase.

[0062] In the present invention, the cancer or tumor includes but is not limited to: lung cancer, melanoma, gastric cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, classical Hodgkin's lymphoma, hematological malignancies, head and neck cancer or nasopharyngeal carcinoma, etc., also includes their combinations, and also includes their metastases or complications.

[0063] Nanobodies

[0064] In a first aspect, the present invention provides an anti-PD-L1 nanobody, wherein the complementary determining region CDR of the anti-PD-L1 nanobody includes CDR1 to CDR3 with the amino acid sequences shown below: (1) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 15, and CDR3 shown in SEQ ID NO: 25; or (2) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 16, and CDR3 shown in SEQ ID NO: 26; or (3) CDR1 shown in SEQ ID NO: 8, CDR2 shown in SEQ ID NO: 16, and CDR3 shown in SEQ ID NO: 27; or (4) CDR1 shown in SEQ ID NO: 9, CDR2 shown in SEQ ID NO: 17, and CDR3 shown in SEQ ID NO: 28; or (5) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 16, and CDR3 shown in SEQ ID NO: 29; or (6) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 18, and CDR3 shown in SEQ ID NO: 29. CDR3 shown in ID NO:30.

[0065] The anti-PD-L1 antigen nanobody provided by the present invention may include a framework region FR, wherein the framework region FR includes FR1 to FR4 with the amino acid sequences shown below: (1') FR1 shown in SEQ ID NO: 1, FR2 shown in SEQ ID NO: 11, FR3 shown in SEQ ID NO: 19, and FR4 shown in SEQ ID NO: 31; or (2') FR1 shown in SEQ ID NO: 2, FR2 shown in SEQ ID NO: 12, FR3 shown in SEQ ID NO: 20, and FR4 shown in SEQ ID NO: 31; or (3') FR1 shown in SEQ ID NO: 3, FR2 shown in SEQ ID NO: 13, FR3 shown in SEQ ID NO: 21, and FR4 shown in SEQ ID NO: 31; or (4') FR1 shown in SEQ ID NO: 4, FR2 shown in SEQ ID NO: 13, FR3 shown in SEQ ID NO: 22, and FR4 shown in SEQ ID NO: 31; or (5') FR1 shown in SEQ ID NO: 5, FR2 shown in SEQ ID NO: 12, FR3 shown in SEQ ID NO: 23, and FR4 shown in SEQ ID NO: 31. or (6′) FR1 shown in SEQ ID NO:5, FR2 shown in SEQ ID NO:14, FR3 shown in SEQ ID NO:24, or FR4 shown in SEQ ID NO:31.

[0066] The antigen binding properties of an antibody are usually determined by three complementary determining regions (CDRs), which are arranged in order with the FR regions, and the FR regions do not directly participate in the binding reaction. These CDRs form a ring structure, and the β-folds formed by the FRs therebetween are close to each other in spatial structure, forming the antigen binding site of the antibody. The CDR region is the sequence of a protein of interest in immunology, and the CDR region of the antibody of the present invention is completely new.

[0067] The amino acid sequence of the anti-PD-L1 antigen Nanobody provided by the present invention may include: a) an amino acid sequence as shown in one of SEQ ID NOs: 33 to 38; or, b) an amino acid sequence having a sequence identity of more than 80% with one of SEQ ID NOs: 33 to 38, and having the function of the amino acid sequence defined in a); specifically, the amino acid sequence in b) specifically refers to: an amino acid sequence as shown in one of SEQ ID NOs: 33 to 38 obtained by substitution, deletion or addition of one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids, or an amino acid sequence as shown in one of SEQ ID NOs: 33 to 38 obtained by addition or reduction of one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids at the N-terminus and / or C-terminus, and having the function of a polypeptide fragment as shown in one of SEQ ID NOs: 33 to 38, for example, specific binding ability to PD-L1. The amino acid sequence in b) may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more homology with one of SEQ ID NOs: 33 to 38. The anti-PD-L1 nanobody provided by the present invention can specifically bind to human PD-L1, block the interaction between PD-L1 and PD-1, increase the expression of IFN-γ and / or IL-2 in T lymphocytes, and inhibit tumor growth.

[0068] The anti-PD-L1 antigen nanobody provided by the present invention can be a humanized antibody, and the humanized nanobody can retain at least one functional property of an antibody, for example, the specific binding ability to PD-L1 or blocking the interaction between PD-L1 and PD-1. Based on the application of the specific complementary determining regions in the present invention, humanized antibodies designed according to the technology in the art should be included in the present invention.

[0069] In a preferred embodiment of the present invention, the inventors have humanized the nanobodies from natural sources of Camelidae, thereby further improving their drug safety and effectively reducing the immunogenicity of the antibodies. Fully humanized heavy chain antibodies often face the problem of poor solubility leading to protein aggregation, and thus cannot be used in actual clinical practice. The decrease in solubility caused by the humanization of nanobodies may be due to the lack of light chains paired with natural monoclonal antibodies in the VH domain (Front Immunol. 2017 Nov 22; 8: 1603). The humanized antibodies obtained by the present invention after framework region modification still maintain a very high solubility, making it possible to use them in actual clinical applications. In a specific embodiment of the present invention, the amino acid sequence of the anti-PD-L1 humanized nanobody is shown in SEQ ID NO: 39 to 44.

[0070] Fusion Protein

[0071] The second aspect of the present invention provides a fusion protein of an anti-PD-L1 nanobody, comprising a first domain of a nanobody as provided in the first aspect of the present invention and a second domain for prolonging the half-life in vivo and / or having a binding effect on effector cells. The fusion protein may be a binding molecule that can specifically bind to cells expressing PD-L1.

[0072] In the second domain, the fragment used to extend the half-life in vivo may include serum albumin or its fragment, polyethylene glycol, a domain that binds serum albumin (such as a nanobody against serum albumin), a polyethylene glycol-liposome complex, etc. In the second domain, the fragment that has a binding effect on effector cells may include an immunoglobulin Fc region, etc., preferably selected from a human immunoglobulin Fc region. The human immunoglobulin Fc region includes mutations for changing the effector function mediated by Fc, and the effector function includes a combination of one or more of CDC activity, ADCC activity, and ADCP activity. The immunoglobulin may be selected from a combination of one or more of IgG, IgA1, IgA2, IgD, IgE, IgM, etc., and the IgG may be specifically selected from a combination of one or more of IgG1, IgG2, IgG3 or IgG4 subtypes, etc. The immunoglobulin Fc region contained in the nanobody fusion protein can cause the fusion protein to form a dimer, while extending the in vivo half-life of the fusion protein and increasing Fc-mediated related activities. In a specific embodiment of the present invention, the immunoglobulin Fc region can be the Fc region of human IgG1, more specifically, it can be a wild-type IgG1 Fc sequence, and the sequence can be introduced with mutations for changing Fc-mediated effector functions, for example, a) mutations that change Fc-mediated CDC activity; b) mutations that change Fc-mediated ADCC activity; or c) mutations that change Fc-mediated ADCP activity. Such mutations are described in the following literature: Leonard G Presta, Current Opinion in Immunology 2008, 20:460-470; Esohe E. Idusogie et al., J Immunol 2000, 164:4178-4184; RAPHAEL A. CLYNES et al., Nature Medicine, 2000, Volume 6, Number 4:443-446; Paul R. Hinton et al., J Immunol, 2006, 176:346-356. In another specific embodiment of the present invention, the amino acid sequence of the immunoglobulin Fc region is selected from one of SEQ ID NOs: 45 to 48.

[0073] In the fusion protein of the anti-PD-L1 nanobody provided by the present invention, a connecting peptide may be provided between the first domain and the second domain. The connecting peptide may be a flexible polypeptide chain composed of alanine (A) and / or serine (S) and / or glycine (G), and the length of the connecting peptide may be 3 to 30 amino acids, preferably 3-9, 9-12, 12-16, 16 to 20. In another specific embodiment of the present invention, the length of the connecting peptide may be 8 or 15.

[0074] Isolated polynucleotides

[0075] The third aspect of the present invention provides an isolated polynucleotide encoding the Nanobody provided in the first aspect of the present invention, or encoding the fusion protein provided in the second aspect of the present invention, and the polynucleotide may be RNA, DNA or cDNA, etc. The method of providing the isolated polynucleotide should be known to those skilled in the art, for example, it can be prepared by automatic DNA synthesis and / or recombinant DNA technology, or it can be isolated from a suitable natural source.

[0076] Constructs

[0077] The fourth aspect of the present invention provides a construct, which contains the isolated polynucleotide provided in the third aspect of the present invention. The construction method of the construct should be known to those skilled in the art. For example, the construct can be constructed by in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology and other methods. More specifically, it can be constructed by inserting the isolated polynucleotide into the multiple cloning site of the expression vector. The expression vector in the present invention generally refers to various commercially available expression vectors well known in the art, such as bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors. The vector may also include one or more regulatory sequences operably connected to the polynucleotide sequence, and the regulatory sequence may include a suitable promoter sequence. The promoter sequence is usually operably connected to the coding sequence of the amino acid sequence to be expressed. The promoter may be any nucleotide sequence that shows transcriptional activity in the selected host cell, including mutant, truncated and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides homologous or heterologous to the host cell. The regulatory sequence may also include a suitable transcription terminator sequence, a sequence recognized by the host cell to terminate transcription. The terminator sequence is linked to the 3' end of the nucleotide sequence encoding the polypeptide, and any terminator that is functional in the host cell of choice can be used in the present invention.

[0078] Generally speaking, suitable vectors may contain a replication origin, a promoter sequence, a convenient restriction enzyme site and one or more selectable markers that function in at least one organism. For example, these promoters may include, but are not limited to, the lac or trp promoter of Escherichia coli; the λ phage PL promoter; eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the methanol oxidase promoter of Pichia pastoris and other known promoters that can control gene expression in prokaryotic or eukaryotic cells or their viruses. Marker genes can be used to provide phenotypic traits for selecting transformed host cells, for example, may include, but are not limited to, dihydrofolate reductase, neomycin resistance and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for Escherichia coli, etc. When the polynucleotide is expressed, the expression vector may also include an enhancer sequence. If the enhancer sequence is inserted into the vector, transcription will be enhanced. The enhancer is a cis-acting factor of DNA, usually about 10 to 300 base pairs, which acts on the promoter to enhance the transcription of the gene.

[0079] Expression system

[0080] The fifth aspect of the present invention provides an antibody expression system, the expression system contains the construct provided by the fourth aspect of the present invention or the polynucleotide provided by the third aspect of the present invention integrated into the genome. Any cell suitable for expression by an expression vector can be used as a host cell, for example, the host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell, specifically including but not limited to Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast, filamentous fungi, plant cells; insect cells of Drosophila S2 or Sf9; CHO, COS, HEK293 cells, or animal cells of Bowes melanoma cells, etc. One or more combinations thereof. The method for constructing the expression system should be known to those skilled in the art, for example, it can be a combination of one or more including but not limited to microinjection, gene gun method, electroporation method, virus-mediated transformation method, electron bombardment method, calcium phosphate precipitation method, etc.

[0081] Immunoconjugates

[0082] The sixth aspect of the present invention provides an immunoconjugate, the immunoconjugate comprising the nanobody provided in the first aspect of the present invention, or the fusion protein provided in the second aspect of the present invention. The immunoconjugate generally further comprises a functional molecule connected (including but not limited to covalently linked, coupled, attached, adsorbed) to the nanobody or fusion protein, the functional molecule may be including but not limited to a detectable marker, a cytotoxin, a radioactive isotope, a biologically active protein, a molecule targeting a tumor surface marker, a molecule that inhibits tumors, a molecule targeting a surface marker of an immune cell, etc., or a combination thereof.

[0083] The method for preparing the immunoconjugate should be known to those skilled in the art. For example, the Nanobody and / or fusion protein can be connected to the functional molecule directly or through a spacer of appropriate length. The connection method can be chemical cross-linking or genetic engineering fusion expression, so as to obtain the immunoconjugate.

[0084] For therapeutic purposes, it may be appropriate to combine with therapeutic effector groups such as radioactive groups, i.e., groups derived from radioisotopes or radionuclides (e.g. 3 H. 14 C. 15 N. 33 P. 35 S. 90 Y. 99 Tc, 111 ln, 123 1. 125 1. 131 1. 201 TI, 213 Bi), a toxin or a cytotoxic group such as a cytostatic group or a group consisting of or including it.

[0085] The immunoconjugate may comprise a nanobody or fusion protein of the invention and a detectable marker. The detectable marker includes, but is not limited to, a fluorescent marker, a chromogenic marker, a protein tag; such as an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, a radioactive material, a positron emitting metal, and a non-radioactive paramagnetic metal ion. More than one marker may also be included. The marker used to label the antibody for detection and / or analysis and / or diagnostic purposes depends on the specific detection / analysis / diagnosis technique and / or method used, such as immunohistochemical staining (tissue) samples, flow cytometry, etc. Suitable markers for detection / analysis / diagnosis techniques and / or methods known in the art are well known to those skilled in the art.

[0086] Nanobodies or fusion proteins of the invention can be coupled to labeling groups (labeled polypeptides), which can then be used, for example, for diagnostic purposes. Suitable labeling groups can be selected from radioisotopes (such as those mentioned above) or groups containing radioisotopes, radionuclides, fluorescent groups (such as fluorescent proteins such as GFP, RFP, etc., dyes, rhodamine, fluorescein and its derivatives such as FITC, cyanine dyes such as and), enzyme groups (such as horseradish peroxidase, alkaline phosphatase, β-galactosidase), chemiluminescent groups, biotin groups, metal particles (such as gold particles), magnetic particles (such as having a core containing magnetite (Fe3O4) and / or maghemite (Fe2O3)), predetermined polypeptide groups, etc.

[0087] The immunoconjugate may comprise a nanobody or fusion protein of the invention and a molecule targeting a surface marker of an immune cell. The molecule targeting a surface marker of an immune cell can recognize an immune cell, which carries the antibody of the invention to the immune cell, and the antibody of the invention can target the immune cell to the tumor cell, thereby utilizing the killing effect of the antibody of the invention while also inducing the immune cell to specifically kill the tumor.

[0088] The immunoconjugate may comprise a nanobody or fusion protein of the present invention and at least one molecule targeting a tumor surface marker or a tumor-suppressing molecule. The tumor-suppressing molecule may be an anti-tumor cytokine or an anti-tumor toxin. For example, the cytokine may be, but is not limited to, IL-12, IL-15, IFN-beta, TNF-alpha, etc. The molecule targeting a tumor surface marker may, for example, synergize with the antibody of the present invention to more accurately target tumor cells.

[0089] The immunoconjugate can also be a chimeric antigen receptor (CAR), which can be expressed in immune cells. The "immune cells" and "immune effector cells" are interchangeable, including: T lymphocytes, NK cells or NKT cells, etc., preferably, NK cells and T lymphocytes. The chimeric antigen receptor generally comprises an extracellular binding region, a transmembrane region and an intracellular signaling region connected in sequence, wherein the extracellular binding region comprises a nano antibody or fusion protein of the present invention. The design of the transmembrane region and the intracellular signaling region based on CAR technology is well known in the art: for example, the transmembrane region adopts the transmembrane region of molecules such as CD8 and CD28, and the intracellular signaling region adopts the intracellular signaling region of the immunoreceptor tyrosine activation motif (ITAM) CD3ζ chain or FcεRIγ tyrosine activation continuation and co-stimulatory signal molecules CD28, CD27, CD137, CD134, MyD88, CD40, etc. More specifically, for T lymphocytes, the first generation of CAR T lymphocytes contains only ITAM in the intracellular signaling region, in which the parts of the chimeric antigen receptor are connected in the following form: scFv-TM-ITAM, which can stimulate anti-tumor cytotoxic effects; the second generation of CAR T lymphocytes adds the intracellular signaling region of CD28 or CD137 (also known as 4-1BB), in which the parts of the chimeric antigen receptor are connected in the following form: scFv-TM-CD28-ITAM or scFv-TM- / CD137-ITAM; the B7 / CD28 or 4-1BBL / CD137 co-stimulation in the intracellular signaling region causes the continuous proliferation of T lymphocytes, and can increase the level of cytokines such as IL-2 and IFN-γ secreted by T lymphocytes, while improving the survival period and anti-tumor effect of CAR T in vivo; the third generation of CAR T lymphocytes, in which the parts of the chimeric antigen receptor are connected in the following form: scFv-TM-CD28-CD137-ITAM or scFv-TM-CD28-CD134-ITAM, further improving the survival period of CAR T in vivo and its anti-tumor effect.

[0090] According to the above, the chimeric antigen receptor prepared using the Nanobody or fusion protein of the present invention can be a Nanobody or fusion protein of the present invention, comprising the following sequentially connected extracellular binding region, transmembrane region and intracellular signaling region: Nanobody or fusion protein of the present invention, CD8 and CD3ζ; Nanobody or fusion protein of the present invention, CD8, CD137 and CD3ζ; Nanobody or fusion protein of the present invention, the transmembrane region of the CD28 molecule (CD28a), the intracellular signaling region of the CD28 molecule (CD28b) and CD3ζ; or Nanobody or fusion protein of the present invention, the transmembrane region of the CD28 molecule, the intracellular signaling region of the CD28 molecule, CD137 and CD3ζ.

[0091] The chimeric antigen receptor is expressed on the surface of immune effector cells, and while utilizing the killing effect of the antibody of the present invention, the immune effector cells can also have a highly specific cytotoxic effect on tumor cells expressing PD-L1.

[0092] Pharmaceutical composition

[0093] The seventh aspect of the present invention provides a pharmaceutical composition, comprising the anti-PD-L1 nanobody provided in the first aspect of the present invention, or the fusion protein of the anti-PD-L1 nanobody provided in the second aspect of the present invention, or the immunoconjugate provided in the sixth aspect of the present invention.

[0094] The pharmaceutical composition may also include various pharmaceutically acceptable carriers in the art. Pharmaceutically acceptable carriers are non-toxic to the recipient at the dosage and concentration used, and may specifically include but are not limited to: buffers, such as acetate, Tris, phosphate, citrate and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); proteins, such as serum albumin, gelatin or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrin; chelating agents such as EDTA; tonicity modifiers such as trehalose and sodium chloride; sugars such as sucrose, mannitol, trehalose or sorbitol; surfactants such as polysorbates; salt-forming counterions such as sodium; metal complexes (such as Zn-protein complexes); and / or nonionic surfactants such as Or polyethylene glycol (PEG). Pharmaceutical preparations for in vivo administration are generally sterile, and methods for achieving sterility of pharmaceutical preparations should be known to those skilled in the art, for example, it can be achieved by filtering with a sterile filter membrane or the like. Those skilled in the art can also select a suitable pharmaceutically acceptable carrier according to the dosage form required for the pharmaceutical composition to prepare it into different dosage forms, for example, the pharmaceutical composition of the present invention can be in various dosage forms including but not limited to tablets, injections, lyophilized agents, etc.

[0095] In the pharmaceutical composition, the content of the fusion protein and the immunoconjugate is usually an effective amount, and the content of the active ingredient corresponding to the effective amount can be determined according to the object to be treated and the specific administration method. For example, based on the total mass of the pharmaceutical composition, the content of the fusion protein and the immunoconjugate can range from about 0.01 to 99%, 0.1 to 70%, 1 to 30%, 0.01 to 0.05%, 0.05 to 0.1%, 0.1 to 0.3%, 0.3 to 0.5%, 0.5 to 1%, 1 to 3%, 3 to 5%, 5 to 10%, 10 to 20%, 20 to 30%, 30 to 50%, 50 to 70%, or 70 to 99%.

[0096] The fusion protein, immunoconjugate and pharmaceutical composition of the present invention can be administered as a single active ingredient, or can be administered in a combination therapy, i.e., in combination with other agents. For example, the combination therapy can be the fusion protein, immunoconjugate, pharmaceutical composition combined with at least one other anti-tumor drug. For another example, the combination therapy can be the fusion protein, immunoconjugate, pharmaceutical composition combined with antibodies targeting other tumor-specific antigens, wherein the antibodies targeting other tumor-specific antigens include, but are not limited to, a combination of one or more of anti-EGFR antibodies, anti-VEGF antibodies, anti-HER2 antibodies, or anti-Claudin18A2 antibodies, etc., and the inhibitor can preferably be a monoclonal antibody.

[0097] Detection Kits

[0098] The eighth aspect of the present invention provides a detection kit, comprising the nano antibody provided in the first aspect of the present invention, the fusion protein provided in the second aspect of the present invention, or the immunoconjugate provided in the sixth aspect of the present invention. The kit may also include: a container, a control (negative or positive control), a buffer, an adjuvant, etc. as needed, and those skilled in the art may select them according to the specific circumstances. The kit may also include instructions for use to facilitate the operation of those skilled in the art.

[0099] The present invention further provides a detection method for detecting PD-L1 protein using the nanobody, including but not limited to qualitative detection, quantitative detection and localization detection. Specifically, the detection method includes but is not limited to immunofluorescence assay, immunohistochemistry and radioimmunoassay.

[0100] A method for detecting whether PD-L1 protein is present in a sample may include: contacting the sample with the nanobody of the present invention; observing whether an antibody complex is formed, and the formation of an antibody complex indicates the presence of PD-L1 protein in the sample. The sample may be a cell and / or tissue sample; the sample may be fixed or dissolved in a medium; and the level of PD-L1 protein in the fixed or dissolved sample is detected. In some embodiments, the detection object may be a cell-containing sample present in a cell preservation fluid. In other embodiments, the nanobody is also conjugated with a fluorescent dye, chemical substance, peptide, enzyme, isotope, label, etc. that can be used for detection or can be detected by other reagents.

[0101] use

[0102] The ninth aspect of the present invention provides the use of the nanoantibody provided in the first aspect of the present invention, or the fusion protein provided in the second aspect of the present invention, or the immunoconjugate provided in the sixth aspect of the present invention, or the pharmaceutical composition provided in the eighth aspect of the present invention in the preparation of a drug for diagnosing, treating or preventing a disease associated with cells expressing PD-L1.

[0103] The "therapeutically effective amount" of the fusion protein, immunoconjugate, and pharmaceutical composition provided by the present invention preferably results in a reduction in the severity of disease symptoms, an increase in the frequency and duration of the asymptomatic period of the disease, or prevents damage or disability caused by the pain of the disease. For example, for the treatment of PD-L1-related tumors (including melanoma), the "therapeutically effective amount" preferably inhibits cell growth or tumor growth by at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, more preferably at least about 50%, more preferably at least about 60%, more preferably at least about 70%, and more preferably at least about 80% relative to an untreated subject. The ability to inhibit tumor growth can be evaluated in an animal model system that predicts the efficacy of human tumors. Alternatively, it can also be evaluated by examining the ability to inhibit cell growth, and this inhibition can be determined in vitro by tests known to those skilled in the art. A therapeutically effective amount of fusion proteins, immunoconjugates, and pharmaceutical compositions can generally reduce tumor size or otherwise alleviate the symptoms of the subject. Those skilled in the art can select a suitable therapeutically effective amount according to actual conditions, for example, the size of the subject, the severity of the subject's symptoms, and the selected specific composition or route of administration. The prescription for treatment (e.g., determination of dosage, etc.) can be determined by a doctor, and factors generally considered include, but are not limited to, the disease being treated, the individual patient's condition, the delivery site, the method of administration, and other factors. A prophylactically effective amount refers to an amount that effectively achieves the desired prophylactic effect at the necessary dose and time. Usually, but not necessarily, since the prophylactic dose is used for the subject before the onset of the disease or in the early stages of the disease, the "prophylactically effective amount" is usually lower than the "therapeutically effective amount". Examples of diseases associated with cells expressing PD-L1 that can be diagnosed, treated and / or prevented by the present invention may include all cancers and tumor entities that express PD-L1, specifically including, but not limited to, lung cancer, melanoma, gastric cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, classical Hodgkin's lymphoma, hematological malignancies, head and neck cancer, and nasopharyngeal carcinoma, which may be early, intermediate or advanced, such as metastatic cancer.

[0104] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0105] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific embodiments rather than for limiting the scope of protection of the present invention.

[0106] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0107] Unless otherwise specified, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related conventional techniques in the art. These techniques have been fully described in existing literature.

[0108] Example 1. Construction of Anti-PDL1 Nanobody Library

[0109] The fusion protein PDL1-HSA (SEQ ID NO: 49) consisting of the PDL1 extracellular domain sequence and the human serum albumin sequence was mixed and emulsified with 1 mg of Freund's complete adjuvant (sigma) to immunize healthy alpacas (Vicugnapacos), and then immunized again after 21 days, for a total of 3 times, to stimulate B cells to express antigen-specific nanoantibodies. One week after the 3 immunizations, 30 ml of alpaca blood was collected with a vacuum blood collection tube, lymphocytes were separated with lymphocyte separation solution (Tianjin Haoyang Huake Biotechnology Co., Ltd.), and total RNA was extracted using the Trizol method. 3 μg of total RNA was reverse transcribed into cDNA using a reverse transcription kit (Invitrogen) according to the instructions, and VHH was amplified using nested PCR. The target VHH nucleic acid fragment was recovered, digested with restriction endonuclease SfiI (NEB), inserted into the phage display vector pcomb3xss (Addgene plasmid #63890; RRID: Addgene_63890) digested with the same enzyme, and ligated with T4 ligase (Takara). The ligation product was transformed into electroporated competent cells ER2738 to construct the Anti-PDL1 nanobody library. The library size was determined to be 1.25×10 8 At the same time, 24 clones were randomly selected for colony PCR detection, and the results showed that the insertion rate of the constructed library was 100%.

[0110] Example 2: Screening and identification of anti-PDL1 nanobodies

[0111] 2.1 Screening of Anti-PDL1 Nanobodies

[0112] The constructed Anti-PDL1 nanobody library was packaged using helper phage M13KO7 (NEB), and the titer of the recombinant phage display library was measured to be 2.88×10 13 PFU / ml. PDL1-HSA was diluted to 2 μg / ml with 100 mM NaHCO3 pH 8.2 coating solution, and 100 μL / well was added to coat the ELISA plate and placed at 4°C overnight. The next day, 200 μL 3% BSA was added and blocked at 37°C for 1 hour, and 100 μL recombinant phage (about 2.88×10 11 PFU / well, from the library constructed in Example 1), at room temperature for 1 hour. Then wash 5 times with PBST (PBS containing 0.1% Tween 20) to remove non-specifically bound phages. The washed ELISA wells were incubated with 1 ml of 0.1M gly-HCl 1mg / ml BSA (pH2.2) buffer for 10 minutes for elution, and neutralized with 1M pH8.0 Tris-HCl. The phage titer was measured and the titer was 5.25×10 6 The above phage eluate was amplified and the titer was determined to be 1.3×10 13 PFU / ml. The fusion protein PDL1-FC (SEQ ID NO: 50) consisting of the PD-L1 extracellular domain sequence and human IgG1 FC was used as the coating protein and blocked with 3% ovalbumin (OVA). The second round of screening was carried out in the same screening process. The titer of the phage in the second round of panning was 2.54×10 8 PFU / ml.

[0113] 2.2 Enzyme-linked immunosorbent assay (ELISA) and TEPITOPE dual screening

[0114] 380 monoclones were selected from the phage titer determination plate of the second round of panning and eluted and cultured in a 96-well plate, and infected and packaged with M13KO7 helper phage to obtain the accumulation of recombinant phage in the supernatant. PDL1-HSA was coated with 200ng / well and blocked with 3% BSA at room temperature for 1h. ELISA was performed with different concentration gradients of PD1-FC (SEQ ID NO: 51), and the binding curve was drawn. The EC90 was calculated to be 2.4μg / mL. After the monoclonal recombinant phage supernatant was mixed with 4μg / mL PD1-FC in equal proportions in a 96-well plate, 100μl / well was taken and incubated in a 96-well plate coated with PDL1-HSA (where only the well with a final concentration of 2μg / mL PD1-FC was added as a control), and incubated at 37°C for 1 hour. After washing with PBST three times, 100 μl HRP-Goat anti-Human IgG Fc (Novex) diluted 1:20000 was added to each well and incubated at 37°C for 1 hour. After washing with PBS three times, TMB color development working solution (Beijing Kangwei Century Biotechnology Co., Ltd.) was added, and after incubation at room temperature for 5 minutes, 1M sulfuric acid was added to terminate the reaction and the OD450nm reading was performed. Among them, the control well PD1-FC showed obvious color development (OD450nm value was 3.375), and the phage competition positive clone well showed weak color development or basically no color development (OD450nm value was less than 0.3). The competition positive clones were selected for sequencing to remove duplicate sequences. The obtained high-affinity positive sequences were further subjected to immunogenicity analysis, and the scores of DRB1*03:01, DRB1*07:01, DRB1*15:01, DRB3*01:01, DRB3*02:02, DRB4*01:01 and DRB5*01:01 alleles closely related to human immunogenicity were calculated by using the prediction tool TEPITOPE (Sturniolo T et al., Nat. Biotechnol. 17:555-561) based on the QAM method, and sequences with a total CDR3TEPITOPE score higher than 4 were excluded, and anti-PD-L1 nanobody sequences with a high degree of humanization were further screened. Most of the CDR3 TEPITOPE total scores of the anti-PD-L1 nanobody finally obtained by the present invention are <-2.0, which is significantly lower than similar anti-PD-L1 nanobodies, which means that the anti-PD-L1 nanobody of the present invention has a lower potential immunogenicity risk.

[0115] After multiple rounds of screening, the inventors finally selected 6 competitively strong positive clones and anti-PDL1 nanobody sequences with low TEPITOPE scores. The full-length sequences are shown in Table 1a, where the underlined regions are CDR regions.

[0116] Table 1a

[0117]

[0118] The framework regions (FR) and complementarity determining regions (CDR regions) of each antibody are shown in Table 1b.

[0119] Table 1b

[0120]

[0121] CDR3 TEPITOPE scores are shown in Table 1c.

[0122] Table 1c

[0123]

[0124]

[0125] Note: PDL1-56 dAb is derived from WO2017 / 020801A1, InnoventNb is derived from CN107686520A, and Nb43 is derived from WO2018 / 233574A1. InnoventNb predicted the TEPITOPE of its CDR32-26 amino acids.

[0126] Example 3: Preliminary evaluation and identification of Anti-PDL1 nanobody

[0127] 3.1 Expression and purification of nanobodies in host Escherichia coli

[0128] The specific positive sequence plasmid obtained by screening was used as a template, and PCR amplification was performed with the high-fidelity enzyme GVP8 (General Biosystems (Anhui) Co., Ltd.), and the histidine tag coding sequence was introduced at the 3' end of the sequence. The PCR product was electrophoresed and the gel was cut to recover a band of about 600 bp. The recovered PCR product was recombined with the pET32a+ vector (Novagen) digested with the endonucleases NdeI (NEB) and EcoRI (NEB) using a recombination kit (Near Shore Protein Technology Co., Ltd.) to construct an E. coli expression plasmid, transform the E. coli competent Top10F', apply an ampicillin-resistant plate, and culture in an incubator at 37°C overnight. The clones on the ampicillin-resistant plate were picked separately, and the plasmids were sequenced to confirm the correct insertion of the sequence on the pET32a+ vector. The E. coli expression plasmid determined by sequencing was transformed into the E. coli expression host Rosetta (DE3) to construct an E. coli expression strain. The recombinant clone was picked and cultured on the ampicillin-resistant plate, and induced to express overnight at 30°C with 1mM IPTG. The bacterial solution induced for expression overnight was ultrasonically disrupted, centrifuged at 12000g at 4°C for 10 minutes, and the supernatant was collected and purified using a Ni column (Borgron Biotechnology Co., Ltd.). The final protein purity reached more than 90%.

[0129] 3.2 Specific binding of Anti-PDL1 nanobody to human PD-L1

[0130] Human PDL1-HSA or HSA (purchased from Sigma) was coated with 200 ng / well at 4°C overnight, and blocked with 5% skim milk powder at room temperature for 1 hour. The purified histidine tag-fused Anti-PDL1 nanobody was diluted to 1 μg / mL, and 100 μL per well was incubated at 37°C for 1 hour. After washing with PBST 3 times, 100 μl / well of 1:5000 diluted mouse anti his tag antibody (R&D Systems, Inc) was added and incubated at room temperature for 1 hour. After washing with PBST, 1:10000 diluted HRP-Goat anti mouse IgG antibody (Thermo Scientific) was added, 100 μl per well, and incubated at room temperature for 1 hour. After washing with PBST, TMB color development working solution (Beijing Kangwei Century Biotechnology Co., Ltd.) was added for color development, and the OD value was detected at 450 nm.

[0131] The test results are shown in Table 2, which show that the 6 clones screened above specifically bind to human PDL1.

[0132] Table 2

[0133]

[0134] 3.3 Binding of Anti-PDL1 Nanobody to Mouse PD-L1

[0135] Mouse mPDL1-HSA fusion protein (SEQ ID NO: 52) was coated with 200 ng / well at 4°C overnight, and blocked with 5% skim milk powder at room temperature for 1 hour. The purified histidine tag-fused Anti-PDL1 nanobody was diluted to 1 μg / mL, and 100 μL per well was incubated at 37°C for 1 hour. After washing with PBST 3 times, 100 μl / well of 1:5000 diluted mouse anti his tag antibody (R&D Systems, Inc) was added and incubated at room temperature for 1 hour. After washing with PBST, 1:10000 diluted HRP-Goat antimouse IgG antibody (Thermo Scientific) was added, 100 μl per well, and incubated at room temperature for 1 hour. After washing with PBST, TMB was added for color development, and the OD value was detected at 450 nm.

[0136] The results showed that the OD value corresponding to the Anti-PDL1 nanoantibody was not significantly different from that of the blank control group without Anti-PDL1 nanoantibody, indicating that the 6 clones obtained by screening did not bind to mouse PDL1.

[0137] 3.4 Competitive ELISA detection of Anti-PDL1 nanobody protein

[0138] PDL1-HSA was coated at 200 ng / well at 4°C overnight, and blocked with 5% skim milk powder at room temperature for 1 hour. The purified histidine tag-fused Anti-PDL1 nanoantibody was diluted in a gradient manner and mixed with 4.8 μg / mL PD1-FC in equal volumes, and 100 μl was incubated at 37°C for 1 hour per well. After washing with PBST 3 times, 100 μl HRP-Goatanti-Human IgG Fc (Novex) diluted 1:20000 was added to each well and incubated at room temperature for 1 hour. After washing with PBS 3 times, TMB substrate was added and incubated at 37°C. After incubation for 5 minutes to develop color, 1M sulfuric acid was added to terminate the reaction, and the OD450nm reading was calculated to obtain the half inhibitory concentration (IC50 value). The smaller the IC50 value, the stronger the specificity of the antibody.

[0139] The results are shown in Table 3, which indicate that the nanobodies screened by the present invention have good binding specificity.

[0140] Table 3

[0141] Clone number IC50(ng / ml) 1A7 50.5 1D1 45.2 1D7 55.1 1G10 62.8 5A8 43.6 6F1 52.7

[0142] Example 4: Humanization of Anti-PDL1 Nanobody

[0143] The humanization method adopts the VHH humanized framework transplantation method (Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath KJ Biol Chem. 2009; 284 (5): 3273-3284). According to the universal humanized VHH framework h-NbBcII10FGLA (PDB number: 3EAK) designed based on sequence homology, the corresponding CDR region is replaced with the CDR region of the Anti-PDL1 nanobody, and the individual amino acids in the FR2 region are further humanized according to the sequence of the humanized antibody DP-47. Each Anti-PDL1 nanobody obtains a variety of humanized variants, and while introducing as many human amino acids as possible, a humanized scheme with high solubility and low polymer formation is selected from it. The humanized nanobody is expressed and purified according to Example 3.1.

[0144] The preferred humanized VHH amino acid sequences are SEQ ID NOs: 39 to 44, as shown in Table 4a, wherein the underlined regions are CDR regions.

[0145] Table 4a

[0146]

[0147] The framework regions (FR) and complementarity determining regions (CDR regions) of each humanized variant are shown in Table 4b.

[0148] Table 4b

[0149]

[0150] The degree of humanization of each humanized Nanobody (by comparing the sequence identity with the closest human gene and allele) was analyzed by IMGT / 3Dstructure-DB (website http: / / www.imgt.org), which can be referred to: Use of Databases and Tools for Antibody Engineering and Humanization, Marie-Paule Lefranc et al., Methods Mol Biol, 907:3-37, 2012. The results are shown in Table 4c.

[0151] Table 4c

[0152] Closest human genes and alleles Sequence identity (%) hu1A7V3 IGHV3-66*01、IGHJ4*01 84.2 hu1D1V3 IGHV3-23*04、IGHJ4*01 88.7 hu1D7V3 IGHV3-23*04、IGHJ4*01 88.7 hu1G10V3 IGHV3-23*04、IGHJ4*01 85.6 hu5A8V3 IGHV3-23*04、IGHJ4*01 88.7 hu6F1V3 IGHV3-64*04、IGHJ4*01 87.6 hu56V1 IGHV3-64*04、IGHJ1*01 78.4 hu56V2 IGHV3-64*04、IGHJ1*01 81.4 InnoventNb IGHV3-66*01、IGHJ5*02 81.2 HualanNb1 IGHV3-NL1*01、IGHJ6*01 72.2 HualanNb2 IGHV3-23*01、IGHJ4*01 78.4 BevacizumabVH IGHV3-30*02、IGHJ4*01 76.8 AdalimumabVH IGHV3-9*01、IGHJ4*01 93.9

[0153] Note: hu56V1 and hu56V2 are derived from SEQ ID NO:33 and SEQ ID NO:34 of WO2017 / 020801A1, respectively, InnoventNb is derived from SEQ ID NO:14 of CN107686520A, Hualan Nb 1 and Hualan Nb 2 are derived from SEQ ID NO:8 and SEQ ID NO:14 of WO2018 / 233574A1, respectively. Bevacizumab and Adalimumab are marketed monoclonal antibodies.

[0154] Example 5: Preparation of Anti-PDL1-Fc Fusion Protein Using Mammalian Cells

[0155] 5.1 Expression and purification of Anti-PDL1 nanobody and Fc fusion protein (Anti-PDL1-Fc)

[0156] The specific positive sequences (SEQ ID NOs: 33-38) and humanized sequences (SEQ ID NOs: 39-44) obtained by screening were converted into base sequences according to the codon preference of CHO cells, and the full-length DNA was obtained by gene synthesis (Nanjing GenScript Biotechnology Co., Ltd.). Using each DNA as a template, PCR amplification was performed with the high-fidelity enzyme GVP8 (Anhui General Biotechnology Co., Ltd.), and the PCR product was electrophoresed and the gel was cut to recover a band of about 600 bp. The recovered PCR product was recombined with the pCDNA3.1 vector containing a signal peptide and a human IgG1 Fc sequence (SEQ ID NO: 45) to construct a cell expression plasmid fused with the Anti-PDL1 nanoantibody and human IgG1Fc. The cell expression plasmid fused with the Anti-PDL1 nanoantibody and human IgG1Fc was extracted using an endotoxin-free plasmid extraction kit (Biomiga). The plasmid was mixed evenly with the transfection reagent PEI (Polysciences, Inc.) at a ratio of 1:3 and allowed to stand for 30 minutes. The mixture was then added to HEK293F cells and cultured in a shaker incubator at 37°C and 5% CO2 for 7 days, and the supernatant was obtained by centrifugation. The supernatant was adjusted to pH 7.0 and loaded onto a Protein A affinity chromatography column (Borgron Biotechnology Co., Ltd.), eluted with 100% 0.1M Gly-HCl (pH 3.0); 10% 1M Tris-HCl (pH 8.5) was added to the eluent in advance. The 100% eluent was diluted to a conductivity of 4ms / cm, adjusted to pH 5.5, centrifuged (8000rpm, 4°C, 10min), and the supernatant was adjusted to pH 5.0 and loaded onto a DSP chromatography column (Borgron Biotechnology Co., Ltd.), eluted linearly with 0-60% eluent (20mM NaAc, 0.5M NaCl, pH 5.0), 2ml / min, 15min. Purity was detected using SEC-HPLC-UV analysis. Detector: Agilent 1100LC; Detection wavelength: 214nm; Mobile phase: 150mM pH7.0 PB + 5% isopropanol; Chromatographic column: Superdex 200Increase 5 / 150GL; Running time: 15 minutes; Column temperature 25°C. Purity is greater than 95%.

[0157] Example 6: Identification of the function of Anti-PDL1-Fc fusion protein in vitro

[0158] 6.1 Identification of Anti-PDL1-Fc Fusion Protein’s Binding Ability to PD-L1

[0159] PDL1-HSA was coated at 200 ng / well at 4°C overnight, and blocked with 5% skim milk powder at room temperature for 1 hour. Anti-PDL1-Fc fusion protein was graded diluted with 1% BSA and incubated at 37°C for 1 hour. After washing with PBST 3 times, 100 μl HRP-Goat anti-Human IgG Fc (Novex) diluted 1:20000 was added to each well and incubated at room temperature for 1 hour. After washing with PBST 3 times, TMB substrate was added and incubated at 37°C. After incubation for 5 minutes to develop color, 1M sulfuric acid was added to terminate the reaction and the OD450nm reading was performed. The results are shown in Table 5.

[0160] Table 5

[0161]

[0162]

[0163] 6.2 Identification of the blocking effect of anti-PD-L1 nanobody Fc fusion protein on PDL1-PD1 interaction (competitive ELISA method)

[0164] PDL1-HSA was coated at 200 ng / well at 4°C overnight and blocked with 5% skim milk powder at room temperature for 1 hour. Anti-PDL1-Fc fusion protein was diluted 5-fold with 1% BSA from a starting concentration of 4 μg / mL, and then mixed with an equal volume of biotin-labeled 4 μg / mL bio-PD1-FC. 100 μL of the mixture was added to a 96-well plate and incubated at 37°C for 1 hour. After washing with PBST three times, 100 μL of HRP-Streptavidin (Jackson ImmunoResearch Inc.) diluted 1:50000 was added to each well and incubated at room temperature for 1 hour. After washing with PBST three times, TMB substrate was added and incubated at 37°C. After incubation for 5 minutes to develop color, 1M sulfuric acid was added to terminate the reaction, and OD450nm readings were taken. The results are shown in Tables 6 and Figure 1 .

[0165] Table 6

[0166]

[0167] The above results indicate that the nanobody of the present invention has a significant blocking effect on the PDL1-PD1 interaction.

[0168] Example 7: Identification of the functional activity of Anti-PDL1-Fc fusion protein in human T lymphocyte cell line

[0169] 7.1 Construction of cell detection strains

[0170] CD5L-OKT3scFv-CD14 (GenBank: ADN42857.1) was synthesized and digested with HindIII-EcoRI (Takara) and inserted into the vector pCDNA3.1 to construct pCDNA3.1-antiCD3TM. Using human PD-L1 as a template, the PDL1 fragment was amplified with high fidelity and recombined and connected into pCDNA3.1-antiCD3TM to construct pCDNA3.1-antiCD3TM-PDL1. CHO cells (Thermo) were transfected and then selected with G418 for 10-14 days to generate the stable cell line CHO-antiCD3TM-PDL1.

[0171] The fragment obtained by amplification with human PD1 as template was recombined with PB513B1-dual-puro vector (Ubao Bio) digested with HindIII-BamHI (Takara) to construct plasmid pB-PD1. The fragment obtained by high-fidelity amplification with template pGL4.30 (Ubao Bio) was recombined with pB-PD1 vector digested with SfiI-XbaI (Takara) to construct pB-NFAT-Luc2p-PD1 plasmid. After the plasmid was successfully constructed, the plasmid was extracted with the endotoxin-free plasmid extraction kit (Biomiga) for transfection of jurkat cells (Stem Cell Bank of Chinese Academy of Sciences). Referring to the method in patent CN 107022571A, jurkat cells were treated to a relatively adherent state by using 0.1 mg / ml poly-D-lysine, and then transfected according to the transfection instructions in the lipofectamine transfection kit (Lipofectamine 3000; Invitrogen); on the third day, RPMI1640 medium (Thermo) containing 10% FBS and 2.5 μg / ml puromycin were used for pressure screening; thereafter, the culture medium was supplemented at regular intervals, and the content of puromycin was gradually increased to 4 μg / ml after the cell viability was restored. Finally, the Jurkat-NFAT-Luc2p-PD1 cell line was obtained.

[0172] 7.2 Identification of the ability of Anti-PDL1-FC fusion protein to block PDL1 and PD1 pathways

[0173] Take CHO-CD3TM-PD-L1 and Jurkat-NFAT-Luc2p-PD-1 cells and count them, and adjust the cell density to 4×10 6 / ml, 25μl was added to each cell in each well of a 96-well plate; in this experiment, Anti-PDL1-Fc fusion protein, positive control group Durvalumab (AstraZeneca) and 56-Fc (SEQ ID NO: 42 from WO2017 / 020801A1), and negative control group ch-175D10 (from US9751934B2 patent) were gradiently diluted with 1% BSA, and 50μl of the above antibodies were added to the cells, so that the final concentration of the antibodies was 130, 43.4, 14.5, 4.82, 1.61, 0.536, 0.179, 0.0595nM; after co-culture at 37°C and 5% CO2 for 6h, 10μl of luciferase substrate was added to each well, shaken on an oscillator for 2min, and read. The operation was as described in the kit (Luciferase Assay Kit; Lot: 0000339727; Promega).

[0174] Figure 2 The results showed that the addition of Anti-PDL1 antibody could block the binding of PD-1 / PD-L1 on the surface of target cells, with a dose-response curve; it was also specific, and ch-175D10 (target: Claudin18.2) could not block the binding of PD-L1 and PD1 pathways.

[0175] Depend on Figure 2 It can also be seen that the ability of the Anti-PDL1 antibody optimized by the present invention to block the binding of PD-1 / PD-L1 on the surface of target cells is better than that of the positive controls Durvalumab and 56-Fc.

[0176] Example 8: Identification of the activation effect of Anti-PDL1-Fc fusion protein on PBMC

[0177] PBMCs were isolated from the peripheral blood of healthy subjects using lymphocyte separation medium (Tianjin Haoyang Huake Biotechnology Co., Ltd.). Recombinant anti-CD3 monoclonal antibody (Jinan Protein Technology Co., Ltd., catalog number GMP-A018) containing a final concentration of 5 μg / ml was plated at 4°C overnight at 50 μl / well, and the cells were diluted to 2×10 with recombinant CD28 monoclonal antibody (Jinan Protein Technology Co., Ltd., catalog number GMP-A063) containing 2 μg / ml. 6 / ml, the supernatant was discarded from the coated plate, and the plates were washed twice with 200μl / well PBS, 200μl cells were added to each well for activation. After 24h of cell activation, 5nM Durvalumab (AstraZeneca) and 5nM Anti-PDL1-Fc fusion protein were added for stimulation. After 3 days of stimulation, the supernatant was collected at 1500rpm for 5min, and the supernatant was used to detect the cytokine IL2 according to the instructions of the kit (purchased from Dakoway).

[0178] Results Figure 3 The anti-PDL1 nanobody fusion protein can enhance the secretion of IL2 by PBMC, and the fold increase of IL2 caused by it is significantly higher than that of the positive control Durvalumab.

[0179] Example 9: Study on the tumor suppressive activity of Anti-PDL1-Fc fusion protein

[0180] The tumor suppressive activity of Anti-PDL1-Fc fusion protein was studied by subcutaneously transplanting MC38 cells expressing human PD-L1 (MC38-PDL1) (Nanjing Galaxy Company) and human peripheral mononuclear cells (PBMC) into NOD / SCID mice.

[0181] The experimental design was as follows: 3×10 6 MC38 cells. 15 days after tumor inoculation, the tumor size was 100-250mm 3 The mice were randomly divided into groups, with 4-6 mice in each experimental group. 100 μl of pooled PBMCs (5×10 5 ). Anti-PDL1 antibody and human IgG1 Fc were administered subcutaneously at a dose of 1 mg / kg, respectively, 3 days after PBMCs implantation, and then administered once a week. PBS was injected as a negative control in a parallel group. Tumor volume measurement: The maximum long axis (L) and maximum wide axis (W) of the tumor were measured with a vernier caliper, and the tumor volume was calculated according to the following formula: V = L × W 2 / 2.

[0182] The experimental results are as follows Figure 4 As shown, over time, the tumor volume of mice vaccinated with Anti-PDL1-Fc was well controlled relative to the control group and did not increase significantly, indicating that Anti-PDL1-Fc had a significant tumor inhibitory effect.

[0183] Example 10: Solubility study of Anti-PDL1-Fc fusion protein

[0184] The purified 100 mg nanoantibody was ultrafiltered using an ultrafiltration tube (Merck Millipore Ltd.), the replacement solution was 5 mM phosphate buffer (pH 7.2) or 5 mM sodium acetate (pH 5.5), and the ultrafiltration was concentrated at 3500 g at 25°C, and the replacement solution was replaced twice, concentrated until it could not be concentrated any further (no significant change in volume after centrifugation for 20 minutes), and the protein content was determined after the concentrate was centrifuged at 8000 g for 10 minutes. This concentration is the solubility under this condition.

[0185] Table 7

[0186] Protein name SEQ ID NO: Solubility (mg / ml) Anti-PDL1-1A7V3-Fc 53 128.8 Anti-PDL1-1D1V3-Fc 54 225.3 Anti-PDL1-1D7V3-Fc 55 132.6 Anti-PDL1-1G10V3-Fc 56 113.41 Anti-PDL1-5A8V3-Fc 57 257.11 Anti-PDL1-6F1V3-Fc 58 59.53

[0187] According to Table 7, the humanized Anti-PDL1-Fc fusion protein optimized by the present invention has good solubility. The PDL1 nanobody in this example humanizes the hydrophilic amino acids at positions 44 and 45 of the original FR2 region into fairly conservative hydrophobic residues G and L of ordinary human antibodies (Table 4a), but does not affect its solubility.

[0188] In summary, the present invention effectively overcomes various shortcomings in the prior art and obtains an antibody product with high industrial utilization value.

[0189] The sequences involved in the present invention are summarized in Table 8.

[0190] Table 8

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. An anti-PD-L1 nanobody, whose complementary determining region CDR includes CDR1 to CDR3 with the amino acid sequences shown below: (1) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:15, and CDR3 shown in SEQ ID NO:25; or (2) CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:16, and CDR3 shown in SEQ ID NO:26; or (3) CDR1 shown in SEQ ID NO:8, CDR2 shown in SEQ ID NO:16, and CDR3 shown in SEQ ID NO:27; or (4) CDR1 shown in SEQ ID NO:10, CDR2 shown in SEQ ID NO:18, and CDR3 shown in SEQ ID NO:

30.

2. The Nanobody according to claim 1, characterized in that The anti-PD-L1 nanobody also includes a framework region FR, each of which includes FR1 to FR4 with the amino acid sequence shown below: (1') FR1 shown in SEQ ID NO: 1, FR2 shown in SEQ ID NO: 11, FR3 shown in SEQ ID NO: 19, FR4 shown in SEQ ID NO: 31; or (2') FR1 shown in SEQ ID NO:2, FR2 shown in SEQ ID NO:12, FR3 shown in SEQ ID NO:20, FR4 shown in SEQ ID NO:31; or (3') FR1 shown in SEQ ID NO:3, FR2 shown in SEQ ID NO:13, FR3 shown in SEQ ID NO:21, FR4 shown in SEQ ID NO:31; or (4′) FR1 shown in SEQ ID NO:5, FR2 shown in SEQ ID NO:14, FR3 shown in SEQ ID NO:24, and FR4 shown in SEQ ID NO:

31.

3. The Nanobody according to claim 1 or 2, characterized in that The anti-PD-L1 nanobody comprises: (a) Amino acid sequence such as SEQ ID NO: 33-35 、 38 any of the Nanobodies shown; or (b) Amino acid sequence and SEQ ID NO: 33-35 、 38. A nanobody having more than 80% identity with any of the sequences shown above and having (a) nanobody function.

4. The Nanobody according to claim 1, characterized in that The anti-PD-L1 nanobody is a humanized antibody, and preferably, its framework region FR includes FR1 to FR4 of an amino acid sequence selected from the following group: FR1 shown in SEQ ID NO:3; FR2 shown in SEQ ID NO:59-61; FR3 shown in SEQ ID NO:62-64; FR4 shown in SEQ ID NO:

65.

5. The Nanobody according to claim 1 or 4, characterized in that The anti-PD-L1 nanobody is a humanized antibody, comprising: (i) Amino acid sequence such as SEQ ID NO: 39-41 、 44 any one of the Nanobodies shown; or (ii) Amino acid sequence similar to SEQ ID NOs: 39 to 41 、 44 A nanobody having more than 80% identity with any of the sequences shown above and having (i) nanobody function.

6. A fusion protein comprising: The first domain is the Nanobody according to any one of claims 1 to 5; as well as The second domain has the effect of extending the half-life in vivo and / or has a binding effect on effector cells.

7. The fusion protein according to claim 6, characterized in that The second domain comprises: An immunoglobulin Fc region, preferably a human immunoglobulin Fc region; and / or Serum albumin or a fragment thereof, a domain that binds serum albumin, polyethylene glycol, a polyethylene glycol-liposome complex, or a combination thereof; and / or A molecule having affinity for a T cell surface molecule and / or capable of binding to a surface molecule present on a T cell; preferably, the surface molecule comprises: CD3.

8. The fusion protein according to claim 7, characterized in that The human immunoglobulin Fc region includes a mutation for changing Fc-mediated effector function, wherein the effector function includes a combination of one or more of CDC activity, ADCC activity, and ADCP activity; or The immunoglobulin is a combination of one or more selected from IgG, IgA1, IgA2, IgD, IgE, and IgM, and the IgG is a combination of one or more selected from IgG1, IgG2, IgG3, or IgG4 subtypes; or The amino acid sequence of the immunoglobulin Fc region is selected from one of SEQ ID NOs: 45 to 48; or A connecting peptide is provided between the first domain and the second domain; the connecting peptide is preferably selected from a flexible polypeptide chain consisting of alanine and / or serine and / or glycine, and the length of the connecting peptide is preferably 3 to 30 amino acids.

9. Use of the Nanobody according to any one of claims 1 to 5, or the fusion protein according to any one of claims 6 to 8 in the preparation of a method for diagnosing, treating or preventing cancer, preferably, the cancer includes: Lung cancer, melanoma, gastric cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, classical Hodgkin lymphoma, hematological malignancies, head and neck cancer, or nasopharyngeal cancer, or a combination thereof.

10. Use of the Nanobody according to any one of claims 1 to 5, or the fusion protein according to any one of claims 6 to 8, in the preparation of a nanoparticle for treating or preventing an infectious disease or a chronic inflammatory disease.

Citation Information

Patent Citations

  • Method for transfecting Jurkat cells

    CN107022571A

  • Anti-PD-L1 nanobody and application thereof

    CN107686520A

  • Monoclonal antibodies against claudin-18 for treatment of cancer

    US9751934B2

  • Single domain antibody for programmed death-ligand (PD-l1) and derived protein thereof

    WO2017020801A1

  • Anti-PD-l1 humanized nanobody and use thereof

    WO2018233574A1